公司简介
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC...
关联新闻
- ArriVent's oral lung cancer therapy fails late-stage trial, shares plunge
ArriVent BioPharma said on Tuesday its oral therapy to treat patients with a rare type of lung cancer did not meet the main goal of delaying disease progression in a late-stage trial, sending shares...